SA
Go ProLog In
COGT
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
12 analysts·Moderate coverage
71
Score
10 Buy (83%)2 Hold (17%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1083%
Hold
217%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$35.00
+11.6%
Consensus
$52.00
+65.8%
Bull
$60.00
+91.3%
12-Month Target Range12 analysts
$35.00$52.00$60.00
Current $31.36Consensus
Current Price
$31.36
Upside to Consensus
$20.64

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+3001.45%
EPS—
FY2028
Rev+120.47%
EPS—
FY2029
Rev+74.06%
EPS+229.76%

Earnings Surprises

Recent Analyst Actions

May 6, 2026H.C. Wainwright
Cogent Biosciences price target raised to $55 from $52 at H.C. Wainwright
Target:$55.00
+48.7%from $36.98
Feb 19, 2026Robert W. Baird
Cogent Biosciences price target raised to $35 from $34 at Baird
Target:$35.00
-8.6%from $38.29
Feb 18, 2026Piper Sandler
Cogent Biosciences price target raised to $52 from $39 at Piper Sandler
Target:$52.00
+38.2%from $37.62
Jan 7, 2026UBS
UBS Starts Cogent (COGT) at Buy
Target:$60.00
+72.5%from $34.78
Jan 6, 2026H.C. Wainwright
Cogent Biosciences price target raised to $52 from $50 at H.C. Wainwright
Target:$52.00
+51.8%from $34.26
Dec 8, 2025Jefferies
Cogent Biosciences price target raised to $48 from $45 at Jefferies
Target:$48.00
+20.1%from $39.97
Nov 11, 2025Raymond James
Cogent (COGT) PT Raised to $60 at Raymond James, 'remains our Analyst Current Favorite'
Target:$60.00
+84.8%from $32.46
Nov 10, 2025Stifel Nicolaus
Cogent upgraded to Buy at Stifel after 'overwhelmingly positive' GIST data
Target:$40.00
+14.4%from $34.97
Nov 10, 2025Wedbush
Wedbush upgrades Cogent to Outperform after better-than-expected trial results
Target:$38.00
+9.3%from $34.76
Oct 15, 2025Stifel Nicolaus
Cogent Biosciences initiated with a Hold at Stifel
Target:$16.00
-3.5%from $16.58
Sep 2, 2025Raymond James
Cogent Biosciences initiated with a Strong Buy at Raymond James
Target:$30.00
+150.0%from $12.00
Aug 25, 2025Guggenheim
Cogent Biosciences price target raised to $20 from $17 at Guggenheim
Target:$20.00
+69.6%from $11.79
Jan 14, 2025H.C. Wainwright
Cogent Biosciences price target lowered to $14 from $17 at H.C. Wainwright
Target:$14.00
+69.7%from $8.25
Sep 24, 2024Citigroup
Cogent (COGT) PT Raised to $15 at Citi
Target:$15.00
+40.8%from $10.65
Sep 3, 2024Citigroup
Citi Reiterates Buy Rating on Cogent (COGT)
Target:$13.00
+18.7%from $10.95
Sep 3, 2024H.C. Wainwright
Cogent Biosciences price target lowered to $17 from $19 at H.C. Wainwright
Target:$17.00
+49.5%from $11.37
Mar 30, 2024Jefferies
Jefferies Assumes Cogent (COGT) at Buy, 'A Validated Tool "KIT" for Mast Cell Diseases & GI Cancer'
Target:$20.00
+197.6%from $6.72
Dec 14, 2022Needham
Needham Initiates Coverage On Cogent Biosciences with Buy Rating, Announces Price Target of $24
Target:$24.00
+94.8%from $12.32
Jun 17, 2022Raymond James
Cogent Biosciences (COGT) Stock Price: Why It Climbed Over 19% Today
Target:$22.00
+139.4%from $9.19
Jun 10, 2022Leerink Partners
Cogent Biosciences price target raised to $15 from $14 at SVB Leerink
Target:$15.00
+39.7%from $10.74

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance